Results 231 to 240 of about 12,986,553 (373)

Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.

JAMA Surgery, 2016
A. Ko, Megan Y. Harada, Galinos Barmparas, Kevin C. Chung, Russell Mason, Dorothy A. Yim, N. Dhillon, D. Margulies, B. Gewertz, Eric J. Ley   +9 more
semanticscholar   +1 more source

Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage-a systematic review and meta-analysis. [PDF]

Res Pract Thromb Haemost
Xiang AJ, Sadafi SL, Principato R, Shaikh A, Nowrouzi M, Eshaghpour A, Li A, Crowther M.   +7 more
europepmc   +1 more source

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis [PDF]

C Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrían V. Hernández, William L. Baker, Paul P. Dobesh, Heleen van Haalen, Kirsty Rhodes, Craig I Coleman   +8 more
openalex   +1 more source

Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.

Blood, 2017
Y. Kamikubo, G. Mendolicchio, A. Zampolli, P. Marchese, A. Rothmeier, Jennifer N. Orje, A. Gale, S. Krishnaswamy, A. Gruber, Henrik Østergaard, L. Petersen, W. Ruf, Z. Ruggeri   +12 more
semanticscholar   +1 more source

Peak and Trough Concentration Ranges of Factor Xa Inhibitors for Preventing Thromboembolic Stroke in Korean Patients with Non-valvular Atrial Fibrillation. [PDF]

Ann Lab Med
Park JS, Lim KH, Kim DH, Lee KM, Woo KS, Han JY.   +5 more
europepmc   +1 more source

Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors

, 2015
Jiabin Yang, Guoqiang Su, Yu Ren, Yang Chen   +3 more
openalex   +1 more source

Risk Factors Associated with Thrombus Development Following Pharmacologic Anticoagulation Reversal with Coagulation Factor Xa [Recombinant], Inactivated-zhzo. [PDF]

Hosp Pharm
Zingale D, Lamore R, Peiffer D, Hinton M, Mangan LE.   +4 more
europepmc   +1 more source

Clinical and pharmacological properties of new oral anticoagulants for the prevention of cerebral thromboembolism: Factor Xa and thrombin inhibitors

, 2012
Yaroslav Winter, Richard Dodel, Alexei Korchounov, Martin Grond, Wolfgang H. Oertel, Tobias Back   +5 more
openalex   +2 more sources

Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation

Therapeutic Advances in Cardiovascular Disease, 2016
D. McCarty, A. Robinson
semanticscholar   +1 more source

New Insights Into Changes in the DNA Methylation Pattern of the SHOX Gene in Patients With Léri‐Weill Dyschondrosteosis

American Journal of Medical Genetics Part A, Volume 200, Issue 3, Page 606-618, March 2026.
ABSTRACT SHOX gene haploinsufficiency is associated with Léri‐Weill dyschondrosteosis (LWD) or idiopathic short stature (ISS) and could be caused by the structural and point mutations in the coding region and by the deletions in SHOX gene regulatory sequences. The role of the duplications in regulatory sequences is ambivalent.
Valeriia Kopytko, Katerina Hirschfeldova, Pavlina Capkova, Roman Solc   +3 more
wiley   +1 more source